VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial

VYNE Therapeutics Inc VYNE has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.
The study did not meet its primary endpoint based on the absolute and percent change relative to baseline in the Atopic Dermatitis Severity Index (ADSI).
The Phase 2a study of FMX114 enrolled 21 patients and was designed to evaluate four weeks of FMX114 treatment in patients with mild-to-moderate AD compared to vehicle control.
Related: VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Data Of FMX114.
Mean ADSI scores for FMX114 and vehicle-treated lesions were 6.6 and 6.9, respectively, at baseline.
The mean reduction in ADSI score from baseline was -4.05 (-60.62% mean reduction) for FMX114 treated lesions compared to -3.48 (-51.32% mean reduction) for vehicle-treated lesions at week 4.
"In addition, as a result of this outcome, our management team and our board of directors will evaluate the company's pipeline and prioritization of activities," said David Domzalski, CEO.
The company expects to report cash and cash equivalents of approximately $43 million as of June 30.
Price Action: VYNE shares are down 33.50% at $0.27 on the last check Wednesday.